Preventive effects of Vitamin D treatment on bleomycin-induced pulmonary fibrosis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zhang, Zongmei ^a,b   Yu, Xiaoting ^a   Fang, Xia ^c   Liang, Aibin ^c   Yu, Zhang ^d   Gu, Pan ^a   Zeng, Yu ^a   He, Jian ^a   Zhu, Hailong ^a   Li, Shuai ^a   Fan, Desheng ^a   Han, Fei ^a   Zhang, Lanjing ^e,f,g,h   Yi, Xianghua ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

^c TONGJI UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

^e University Medical Centre Princeton   (United States)

^f RUTGERS UNIVERSITY   (United States)

^g RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^h RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; FIBRIN; HYDROXYPROLINE; VITAMIN D;

ANIMAL; CHEMICALLY INDUCED; DIETARY SUPPLEMENT; MALE; METABOLISM; MOUSE; PATHOLOGY; PULMONARY FIBROSIS;

ANIMALS; BLEOMYCIN; DIETARY SUPPLEMENTS; FIBRIN; HYDROXYPROLINE; MALE; MICE; PULMONARY FIBROSIS; VITAMIN D;

EID: 84948799381     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17638     Document Type: Article

References (39)

1. Raghu, G. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 183, 788-824 (2002).
2. Travis, W. D. et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 188, 733-748 (2013).
3. Larsen, B. T. & Colby, T. V. Update for pathologists on idiopathic interstitial pneumonias. Arch Pathol Lab Med. 136, 1234-1241 (2012).
4. Scotton, C. J. & Chambers, R. C. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest. 132, 1311-1321 (2007).
5. Teitelbaum, S. L. et al. Calcifediol in chronic renal insufficiency. Skeletal response. JAMA. 235, 164-167 (1976).
6. Tsukamoto, Y. et al. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis. 35, 458-464 (2000).
7. Repo, J. M. et al. Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. Kidney Int. 72, 977-984 (2007).
8. Tan, X., Li, Y. & Liu, Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am SocNephro. 17, 3382-3393 (2007).
9. Zhang Y. et al. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol. 21, 966-973 (2010).
10. Xiong, M. et al. Loss of vitamin D receptor in chronic kidney disease: a potential mechanism linking inflammation to epithelialto-mesenchymal transition. Am JPhysiol Renal Physiol. 303, F1107-1115 (2012).
11. Garcia, I. M. et al. Role of mitochondria in paricalcitol mediated cytoprotection during obstructive nephropathy. Am J Physiol Renal physiol. 302, F1595-1605 (2012).
12. Ito, I. et al. A nonclassical vitamin D receptor pathway suppresses renal fibrosis. Journal Clin Invest. 123, 4579-4594 (2013).
13. Dasarathy J. et al. Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int. 34, e118-127 (2014).
14. Baur, K. et al. Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate in HCV patients. Liver Int. 32, 635-643 (2012).
15. Abu-Mouch, S. et al. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World JGastroenterol. 17, 5184-5190 (2011).
16. Kitson M. T. et al. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol. 58, 467-472 (2013).
17. Mascitelli, L., Pezzetta, F. & Goldstein, M. R. Vitamin D and mortality from pulmonary fibrosis. Chest. 137, 495-496 (2010).
18. Forli L. et al. Vitamin D deficiency, bone mineral density and weight in patients with advanced pulmonary disease. J Intern Med. 256, 56-62 (2004).
19. Mannino, D. M. Is Vitamin D's "Moment in the Sun" Behind Us Chest. 145, 5-6 (2014).
20. Jones, A. W. & Reeve, N. L. Ultrastructural study of bleomycin-induced pulmonary changes in mice. J Pathol. 124, 227-233 (1978).
21. Hardie, W. D., Glasser, S. W. & Hagood, J. S. Emerging concepts in the pathogenesis of lung fibrosis. Am J Pathol. 175, 3-16 (2009).
22. Phan, S. H. The myofibroblast in pulmonary fibrosis. Chest. 122, 286S-289S (2002).
23. Zhang, G. Y. et al. Vitamin D: a novel therapeutic approach for keloid, an in vitro analysis. Br J Dermatol. 164, 729-737 (2011).
24. Ramirez, A. M. et al. Vitamin D inhibition of pro-fibrotic effects of transforming growth factor beta1 in lung fibroblasts and epithelial cells. J Steroid Biochem Mol Biol. 118, 142-150 (2010).
25. Richeldi, L. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. The New England journal of medicine. 370, 2071-82(2014).
26. King T. E. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. The New England journal of medicine. 370, 2083-92(2014).
27. Song, B. J. & Rockey, D. C. Status of research on vitamin D supplementation in treating or preventing liver fibrosis. Liver Int. 33, 653-655 (2013).
28. Bonventre, J. V. Antifibrotic vitamin D analogs. J Clinical Invest. 123, 4570-4573 (2013).
29. Tan, X., Li, Y. & Liu, Y. Therapeutic role and potential mechanisms of active Vitamin D in renal interstitial fibrosis. J Steroid Biochem Mol Biol. 103, 491-496 (2007).
30. Mert, H. et al. Vitamin levels in lung tissue of rats with bleomycin induced pulmonary fibrosis. J Nutr Sci Vitaminol. 55, 186-190 (2009).
31. Mubarak, K. K. et al. Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis. Eur Respir J. 39, 133-140 (2012).
32. Froudarakis, M. et al. Revisiting bleomycin from pathophysiology to safe clinical use. Crit Rev Oncol Hematol. 87, 90-100 (2013).
33. Adamson, I. Y. & Bowden, D. H. The pathogenesis of bloemycin-induced pulmonary fibrosis in mice. Am J Pathology. 77, 185-197 (1974).
34. Piguet, P. F. et al. Resistance of TNF/LT alpha double deficient mice to bleomycin-induced fibrosis. Int J Exp Pathol. 78, 43-48 (1997).
35. Liu, T. et al. Telomerase activity is required for bleomycin-induced pulmonary fibrosis in mice. J Clin Invest. 117, 3800-3809 (2007).
36. Ding N. et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell. 153, 601-613 (2013).
37. Li, Y. et al. 1,25-dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int. 68, 1500-1510 (2005).
38. Ashcroft, T. et al. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. Journal of clinical pathology. 41, 467-70(1988).
39. Yi, X. et al. Transmission electron microscopy of sputum deposition in the diagnosis of pulmonary alveolar proteinosis. Ultrastruct Pathol. 36, 153-159 (2012).